Best practices for the management of local-regional recurrent chordoma: a position paper by the chordoma global consensus group
A. Gronchi
(1)
,
P. Fossati
(2)
,
T. Akiyama
(3)
,
C. Alapetite
(4)
,
M. Baumann
(5)
,
Jean-Yves Blay
(6)
,
S. Bolle
(7)
,
S. Boriani
,
P. Bruzzi
(1)
,
R. Capanna
(8)
,
A. Caraceni
(1)
,
R. Casadei
,
V. Colia
,
J. Debus
(9)
,
T. Delaney
(10)
,
A. Desai
(11)
,
P. Dileo
(12)
,
S. Dijkstra
(13)
,
F. Doglietto
(14)
,
A. Flanagan
(15)
,
S. Froelich
(16)
,
P A. Gardner
(17)
,
Hans Gelderblom
(13)
,
Z L. Gokaslan
(18)
,
R. Haas
(19)
,
C. Heery
(20)
,
N. Hindi
(21)
,
P. Hohenberger
(22)
,
F. Hornicek
(23)
,
R. Imai
(24)
,
L. Jeys
(25)
,
R L. Jones
(26)
,
Bernd Kasper
(22)
,
A. Kawai
(27)
,
M. Krengli
(28)
,
A. Leithner
(29)
,
I. Logowska
(30)
,
J. Martin Broto
(21)
,
D. Mazzatenta
(1)
,
C. Morosi
(1)
,
P. Nicolai
(14)
,
O J. Norum
,
S. Patel
(31)
,
Nicolas Penel
(32)
,
P. Picci
,
S. Pilotti
(1)
,
S. Radaelli
(1)
,
F. Ricchini
(1)
,
P. Rutkowski
(30)
,
S. Scheipl
(33)
,
C. Sen
(34)
,
E. Tamborini
(1)
,
K A. Thornton
(23)
,
B. Timmermann
(35)
,
V. Torri
,
P U. Tunn
(36)
,
M. Uhl
(22)
,
Y. Yamada
(37)
,
D C. Weber
(38)
,
D. Vanel
,
P P. Varga
,
C La Vleggeert-Lankamp
(39)
,
Paolo Casali
,
J. Sommer
1
Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan]
2 ESMO - European Institute of Oncology [Milan]
3 Saitama University
4 Institut Curie [Paris]
5 University of Dresden Medical School
6 Centre Léon Bérard [Lyon]
7 IGR - Institut Gustave Roussy
8 UniPi - University of Pisa [Italy] = Università di Pisa [Italia] = Université de Pise [Italie]
9 University Medical Center Heidelberg
10 Massachusetts General Hospital [Boston]
11 Queen Elizabeth Hospital
12 UCLH - University College London Hospitals
13 Universiteit Leiden = Leiden University
14 UniBs - Università degli Studi di Brescia = University of Brescia
15 Cancer Research UK London Research Institute
16 Hôpital Lariboisière
17 University of Pittsburgh School of Medicine
18 Providence University
19 NKI - Netherlands Cancer Institute
20 NCI-NIH - National Cancer Institute [Bethesda]
21 Hospital Universitario Virgen del Rocío [Sevilla]
22 University of Heidelberg, Medical Faculty
23 HMS - Harvard Medical School [Boston]
24 Chiba University Hospital
25 Queens Elizabeth Hospital [Birmingham]
26 Royal Marsden NHS Foundation Trust
27 National Cancer Center Research Institute [Tokyo]
28 Università del Piemonte Orientale - Dipartimento DISIT Italy
29 Medical University of Graz = Medizinische Universität Graz
30 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
31 MD Anderson Cancer Center [Houston]
32 METRICS - Evaluation des technologies de santé et des pratiques médicales - ULR 2694
33 University Hospital Graz
34 NYU Langone Medical Center - New York University Langone Medical Center
35 University of Duisbourg-Essen
36 Helios Klinikum [Erfurt]
37 Memorial Sloane Kettering Cancer Center [New York]
38 PSI - Paul Scherrer Institut
39 LUMC - Leiden University Medical Center
2 ESMO - European Institute of Oncology [Milan]
3 Saitama University
4 Institut Curie [Paris]
5 University of Dresden Medical School
6 Centre Léon Bérard [Lyon]
7 IGR - Institut Gustave Roussy
8 UniPi - University of Pisa [Italy] = Università di Pisa [Italia] = Université de Pise [Italie]
9 University Medical Center Heidelberg
10 Massachusetts General Hospital [Boston]
11 Queen Elizabeth Hospital
12 UCLH - University College London Hospitals
13 Universiteit Leiden = Leiden University
14 UniBs - Università degli Studi di Brescia = University of Brescia
15 Cancer Research UK London Research Institute
16 Hôpital Lariboisière
17 University of Pittsburgh School of Medicine
18 Providence University
19 NKI - Netherlands Cancer Institute
20 NCI-NIH - National Cancer Institute [Bethesda]
21 Hospital Universitario Virgen del Rocío [Sevilla]
22 University of Heidelberg, Medical Faculty
23 HMS - Harvard Medical School [Boston]
24 Chiba University Hospital
25 Queens Elizabeth Hospital [Birmingham]
26 Royal Marsden NHS Foundation Trust
27 National Cancer Center Research Institute [Tokyo]
28 Università del Piemonte Orientale - Dipartimento DISIT Italy
29 Medical University of Graz = Medizinische Universität Graz
30 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
31 MD Anderson Cancer Center [Houston]
32 METRICS - Evaluation des technologies de santé et des pratiques médicales - ULR 2694
33 University Hospital Graz
34 NYU Langone Medical Center - New York University Langone Medical Center
35 University of Duisbourg-Essen
36 Helios Klinikum [Erfurt]
37 Memorial Sloane Kettering Cancer Center [New York]
38 PSI - Paul Scherrer Institut
39 LUMC - Leiden University Medical Center
M. Baumann
- Fonction : Auteur
- PersonId : 740827
- IdHAL : malvina-baumann
- ORCID : 0000-0002-7706-3013
Jean-Yves Blay
- Fonction : Auteur
- PersonId : 935658
- IdHAL : jean-yves-blay
- ORCID : 0000-0001-7190-120X
- IdRef : 069035407
S. Boriani
- Fonction : Auteur
R. Casadei
- Fonction : Auteur
V. Colia
- Fonction : Auteur
O J. Norum
- Fonction : Auteur
Nicolas Penel
- Fonction : Auteur
- PersonId : 769049
- ORCID : 0000-0001-5243-1548
- IdRef : 061101109
P. Picci
- Fonction : Auteur
V. Torri
- Fonction : Auteur
D. Vanel
- Fonction : Auteur
P P. Varga
- Fonction : Auteur
Paolo Casali
- Fonction : Auteur
J. Sommer
- Fonction : Auteur
Résumé
Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.
Domaines
Sciences du Vivant [q-bio]| Origine | Publication financée par une institution |
|---|
